A complementary approach is to evaluate SV “burden” in cases compared to controls (e.g., number of SV per person). 48,49 This tests an explicitly multigenic model whereby many rare but different genomic disruptions impact disease risk. Increased SV burden in SCZ cases has been reported by multiple groups. 47,48,50 One report found more rare SV in SCZ cases (odds ratio, OR=1.15), particularly for large deletions (OR=3.6). 48 De novo SV are also more common in SCZ cases. 45 For BIP, there are reports of increased 51–53 and similar SV burden in cases versus controls 54,55 De novo SV may be relevant in BIP (OR=4.8), particularly in cases with earlier ages of onset (OR=6.3). 53
